Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28219663 | 0.92 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TDP1EPHX1 | |
| SCHEMBL2802304 | 0.87 | — | — | |
| SCHEMBL7665362 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2TDP1THRB | |
| SCHEMBL4347775 | 0.78 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2TDP1THRBEPHX1 | |
| SCHEMBL2804500 | 0.78 | — | — | |
| SCHEMBL3235400 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1THRB | |
| SCHEMBL3243068 | 0.75 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TDP1THRB | |
| SCHEMBL4798734 | 0.75 | ALDH1A1 (0.61) | ALDH1A1SMN1; SMN2TDP1THRBEPHX1 | |
| SCHEMBL3238846 | 0.73 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TDP1THRBEPHX1 | |
| SCHEMBL11769136 | 0.72 | ALDH1A1 (0.50) | ALDH1A1SMN1; SMN2TDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404860-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2013-03-26 | — | — | US | disclosed |
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | SHIIGI HIROFUMI (JP) | 2012-11-15 | — | — | US | disclosed |
| US-8258313-B2 | Compound having hydantoin ring and method of producing the same | TOKUYAMA CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| EP-2172459-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | Tokuyama Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289705-A1 | COMPOUND HAVING HYDANTOIN RING AND METHOD OF PRODUCING THE SAME | CASP14, CYP8B1, DDT | ALDH1A1 2059/4885SMN1; SMN2 1193/4885TDP1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.